Pulse Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

PLSE$58.17+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except par value)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$44,365	$61,139
Prepaid expenses and other current assets	963	1,008
Total current assets	45,328	62,147
Property and equipment, net	1,528	1,961
Intangible assets, net	1,886	2,551
Goodwill	2,791	2,791
Right-of-use assets	7,256	8,062
Other assets	365	365
Total assets	$59,154	$77,877
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$1,836	$1,573
Accrued expenses	3,814	2,595
Lease liability, current	1,058	896
Related party note payable, current	—	917
Total current liabilities	6,708	5,981
Lease liability, less current portion	8,086	9,144
Related party note payable, less current	—	65,000
Total liabilities	14,794	80,125
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding	—	—
Common stock, $0.001 par value; authorized – 500,000 shares; issued and outstanding – 55,144 shares and 37,235 shares at December 31, 2023 and 2022, respectively	55	37
Additional paid-in capital	381,220	292,420
Accumulated other comprehensive income (loss)	—	—
Accumulated deficit	(336,915)	(294,705)
Total stockholders’ equity (deficit)	44,360	(2,248)
Total liabilities and stockholders’ equity	$59,154	$77,877

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.